Cargando…

Preparation and Storage of Cryoprecipitate Derived from Amotosalen and UVA-Treated Apheresis Plasma and Assessment of In Vitro Quality Parameters

Cryoprecipitate is a plasma-derived blood product, enriched for fibrinogen, factor VIII, factor XIII, and von Willebrand factor. Due to infectious risk, the use of cryoprecipitate in Central Europe diminished over the last decades. However, after the introduction of various pathogen-reduction techno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovacic Krizanic, Katarina, Prüller, Florian, Rosskopf, Konrad, Payrat, Jean-Marc, Andresen, Silke, Schlenke, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317929/ https://www.ncbi.nlm.nih.gov/pubmed/35890049 http://dx.doi.org/10.3390/pathogens11070805

Ejemplares similares

Evaluation of amotosalen and UVA pathogen‐reduced apheresis platelets after 7‐day storage
por: Cancelas, Jose A., et al.
Publicado: (2022)

Pathogen inactivation treatment of triple‐dose apheresis platelets with amotosalen and ultraviolet a light
por: Infanti, Laura, et al.
Publicado: (2022)

Profils d’anticorps dans le plasma de convalescent COVID-19 traité pour traitement de réduction des agents pathogènes par Amotosalen/UVA
por: Corash, Laurence, et al.
Publicado: (2021)

Antibody profiles in COVID‐19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment
por: Bagri, Anil, et al.
Publicado: (2022)

A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment
por: Knutson, F, et al.
Publicado: (2015)

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
por: Bubinski, Michal, et al.
Publicado: (2021)

Cryoprecipitate therapy
por: Nascimento, B., et al.
Publicado: (2014)

The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates
por: Nebie, Ouada, et al.
Publicado: (2019)

Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light
por: Lanteri, Marion C., et al.
Publicado: (2020)

Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light
por: Hindawi, S.I., et al.
Publicado: (2022)

Factors affecting the quality of cryoprecipitate
por: Subramaniyan, Rajeswari, et al.
Publicado: (2017)

Perioperative Cryoprecipitate Waste Reduction
por: Burk, Camden, et al.
Publicado: (2021)

Use of Cryoprecipitate in Newborn Infants
por: Tyagi, Manvi, et al.
Publicado: (2023)

Pathogen reduction of double‐dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects
por: Rosskopf, Konrad, et al.
Publicado: (2020)

Differences in coagulation-relevant parameters: Comparing cryoprecipitate and a human fibrinogen concentrate
por: Stanford, Sophia, et al.
Publicado: (2023)

Cryoprecipitate as an alternative to platelet transfusion in thrombocytopenia
por: Crispin, Philip, et al.
Publicado: (2021)

Effects of pathogen reduction technology and storage duration on the ability of cryoprecipitate to rescue induced coagulopathies in vitro
por: Thomas, Kimberly A., et al.
Publicado: (2021)

Initial Results of Empirical Cryoprecipitate Transfusion in the Treatment of Isolated Severe Traumatic Brain Injury: Use of In-house-produced Cryoprecipitate
por: SHIBAHASHI, Keita, et al.
Publicado: (2019)

MANUTENÇÃO DOS NÍVEIS DE ANTICORPOS NEUTRALIZANTES (NAB) E DE LIGAÇÃO PARA PROTEÍNAS DE NUCLEOCAPSÍDEOS (NP) DE SARS-CoV-2 EM UNIDADES DE PLASMA DE DOADORES CONVALESCENTES (CCP) TRATADOS POR AMOTOSALEN/UVA (A/UVA)
por: Wendel, S., et al.
Publicado: (2020)

Variability in response to cryoprecipitate treatment for hemostatic defects in uremia.
por: Triulzi, D. J., et al.
Publicado: (1990)

Autologous Cryoprecipitate for Attaching Conjunctival Autografts after Pterygium Excision
por: Anbari, Anas A.
Publicado: (2013)

Effects of amotosalen treatment on human platelet lysate bioactivity: A proof-of-concept study
por: Christensen, Christian, et al.
Publicado: (2020)

Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen‐reduction technology
por: Girard, Yvette A., et al.
Publicado: (2020)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days
por: Infanti, Laura, et al.
Publicado: (2019)

Assessment of dengue virus inactivation in random donor platelets using amotosalen and ultraviolet A illumination
por: Kumar, Ankit, et al.
Publicado: (2022)

Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate
por: Collins, P. W., et al.
Publicado: (2014)

A retrospective review of cryoprecipitate transfusion practice in Kuala Lumpur Hospital
por: Iliassa, Intan Iliana, et al.
Publicado: (2016)

Influence of canine donor plasma hemostatic protein concentration on quality of cryoprecipitate
por: Drinkhouse, Macy, et al.
Publicado: (2018)

Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study
por: Hatzl, Stefan, et al.
Publicado: (2021)

Impact of UVA exposure on psychological parameters and circulating serotonin and melatonin
por: Gambichler, Thilo, et al.
Publicado: (2002)

Cold storage of platelets in additive solution: the impact of residual plasma in apheresis platelet concentrates
por: Marini, Irene, et al.
Publicado: (2019)

Apheresis in Neurological Disorders
por: Dorst, Johannes
Publicado: (2020)

Apheresis and Covid-19
por: Griveas, Ioannis
Publicado: (2022)

Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance
por: Stivala, Simona, et al.
Publicado: (2017)

Determination of di-2-ethylhexyl phthalate levels in human blood plasma and cryoprecipitates.
por: Marcel, Y L
Publicado: (1973)

Effect of cryoprecipitate transfusion without ABO group consideration: A nightmare experience
por: Sahoo, Dibyajyoti, et al.
Publicado: (2022)

Comparison of Bacterial Risk in Cryo AHF and Pathogen Reduced Cryoprecipitated Fibrinogen Complex
por: Lu, Thea, et al.
Publicado: (2022)

Protein Concentrations in Stored Pooled Platelet Concentrates Treated with Pathogen Inactivation by Amotosalen Plus Ultraviolet a Illumination
por: Arnason, Niels Arni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qtjoohcres709laf1um2ksike6